X
Access Company Profiles

Get business overview, business operations details specific to this market, products and services, latest developments and more...

Business Email

Select Companies

 

Clinical Trials Support Services Companies

This report lists the top Clinical Trials Support Services companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Clinical Trials Support Services industry.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Clinical Trials Support Services Top Companies

  1. IQVIA

  2. Roche

  3. LabCorp

  4. Eli Lilly and Company

  5. Novo Nordisk

*Disclaimer: Top companies sorted in no particular order

Clinical Trials Support Services Market Major Players

Clinical Trials Support Services Market Concentration

Clinical Trials Support Services  Market Concentration

Clinical Trials Support Services Company List

                            • Charles River Laboratories International Inc.

                            • Laboratory Corporation of America Holdings

                            • Eli Lilly and Company

                            • Icon PLC

                            • Novo Nordisk AS

                            • Parexel International Corporation

                            • Pfizer Inc.

                            • Thermo Fisher Scientific Inc. (PPD Inc.)

                            • Iqvia Holdings Inc.

                            • F. Hoffmann-La Roche Ltd

                            • Sanofi

                            • Syneos Health


                        Specific to Clinical Trials Support Services Market
                        Need More Details On Market Players And Competitors?
                        Download PDF

                        Clinical Trial Support Services Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)